Laveneziana Pierantonio, Sesé Lucile, Gille Thomas
Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Universitaire APHP-Sorbonne Université, sites Pitié-Salpêtrière, Saint-Antoine et Tenon, Service des Explorations Fonctionnelles de la Respiration, de l'Exercice et de la Dyspnée (Département R3S), Paris, France.
Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France.
Breathe (Sheff). 2021 Sep;17(3):210065. doi: 10.1183/20734735.0065-2021.
Coronavirus disease 2019 (COVID-19) is a disease caused by a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the predisposing and protecting factors have not been fully elucidated. COVID-19 primarily impacts the respiratory system, and can result in mild illness or serious disease leading to critical illness requiring admission to the intensive care unit due to respiratory failure. After hospital discharge, the more commonly described pulmonary function anomalies are alterations in diffusing capacity and the loss of lung volume. Reduction of inspiratory muscle contraction may also be underestimated. This article will focus on the pathophysiology of pulmonary function anomalies in COVID-19 survivors. We will discuss current advances and provide future directions and also present our perspective on this field.
2019冠状病毒病（COVID-19）是一种由新型冠状病毒，即严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的疾病，其易感因素和保护因素尚未完全阐明。COVID-19主要影响呼吸系统，可导致轻症或重症，重症可导致因呼吸衰竭而需入住重症监护病房的危重症。出院后，较常描述的肺功能异常是弥散功能改变和肺容积丧失。吸气肌收缩力的降低可能也被低估了。本文将聚焦于COVID-19康复者肺功能异常的病理生理学。我们将讨论当前的进展并提供未来方向，同时也阐述我们对该领域的观点。
